Current and future impact of clinical gastrointestinal research on patient care in diabetes mellitus

Timothy R Koch, Timothy R Shope, Michael Camilleri

Abstract
The worldwide rise in the prevalence of obesity supports the need for an increased interaction between ongoing clinical research in the allied fields of gastrointestinal medicine/surgery and diabetes mellitus. There have been a number of clinically-relevant advances in diabetes, obesity, and metabolic syndrome emanating from gastroenterological research. Gastric emptying is a significant factor in the development of upper gastrointestinal symptoms. However, it is not the only mechanism whereby such symptoms occur in patients with diabetes. Disorders of intrinsic pacing are involved in the control of stomach motility in patients with gastroparesis; on the other hand, there is limited impact of glycemic control on gastric emptying in patients with established diabetic gastroparesis. Upper gastrointestinal functions related to emptying and satiation are significantly associated with weight gain in obesity. Medications used in the treatment of diabetes or metabolic syndrome, particularly those related to pancreatic hormones and incretins affect upper gastrointestinal tract function and reduce hyperglycemia and facilitate weight loss. The degree of gastric emptying delay is significantly correlated with the weight loss in response to liraglutide, a glucagon-like peptide-1 analog. Network meta-analysis shows that liraglutide is one of the two most efficacious medical treatments of obesity, the other being the combination treatment phentermine-topiramate. Interventional therapies for the joint management of obesity and diabetes mellitus include newer endoscopic procedures, which require long-term follow-up and bariatric surgical

ORCID number: Timothy R Koch (0000-0002-8026-9653); Timothy R Shope (0000-0002-5189-8936); Michael Camilleri (0000-0001-6472-7514).

Supported by the grant from National Institutes of Health, No. R01-DK67071.

Conflict-of-interest statement: Koch TR and Shope TR have no conflict of interest to report regarding the publication of this paper. Camilleri M received support from Novo Nordisk to conduct research on liraglutide.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Corresponding author to: Timothy R Koch, MD, Doctor, Professor, Center for Advanced Laparoscopic General and Bariatric Surgery, MedStar Washington Hospital Center and Georgetown University School of Medicine, POB South, Suite 301, 106 Irving Street, NW, Washington, DC 20010, United States. timothy.r.koch@medstar.net Telephone: +1-202-8777788 Fax: +1-877-6808198 Received: July 23, 2018
procedure for which long-term follow up shows advantages for individuals with diabetes. Newer bariatric procedures are presently undergoing clinical evaluation. On the horizon, combination therapies, in part directed at gastrointestinal functions, appear promising for these indications. Ongoing and future gastroenterological research when translated to care of individuals with diabetes mellitus should provide additional options to improve their clinical outcomes.

Key words: Obesity; Gastric emptying; Diabetes mellitus; Gastric bypass; Bariatric surgery; Weight loss

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The worldwide prevalence of obesity continues to rise. Delayed gastric emptying and impaired gastric accommodation result in upper gastrointestinal symptoms, through intrinsic nerve and pacemaker dysfunction. Glycemic control has a limited effect on gastric emptying in diabetic gastroparesis. Treatment of diabetes with pancreatic hormones and incretins inhibits gastric emptying, reduces hyperglycemia, and facilitates weight loss. Meta-analysis shows that glucagon-like peptide-1 analog, liraglutide, is one of the two most efficacious treatments of obesity. Bariatric surgery and endoscopic interventions are efficacious in diabetes and obesity, but long term follow-up is required for endoscopic interventions as well as for newer bariatric procedures. On the horizon, combination therapies directed at gastrointestinal function appear promising for these indications.

INTRODUCTION

In a recent international study of 195 countries, the prevalence of obesity doubled in more than 70 countries since 1980[1]. This worldwide rise in the prevalence of obesity supports the need for an increased interaction between ongoing clinical research in fields of gastrointestinal medicine/surgery and diabetes mellitus. There have been a number of clinically-relevant advances in diabetes, obesity and metabolic syndrome, emanating from gastrointestinal research. These advances include newer information in pharmacological or medical care, endoscopic procedures, and bariatric surgical procedures.

The most exciting gastrointestinal research areas relevant to diabetes are focused on the stomach and on weight loss, with the goals of resolution of hyperglycemia and/or prevention of secondary complications of diabetes mellitus. Ongoing studies have focused on the stomach because patients with diabetes develop upper gastrointestinal symptoms, including the syndrome of gastroparesis. In addition, pharmacological treatments and bariatric procedures directed to the stomach have been the most efficacious treatments of obesity. Some of these clinical gastrointestinal research observations are considered likely to impact patient care in diabetes mellitus and/or obesity and may thus lead to improved patient outcomes.

OBSERVATIONS RELATED TO UPPER GASTROINTESTINAL SYMPTOMS AND GLYCEMIC CONTROL IN DIABETES MELLITUS

Delayed stomach emptying is associated with upper gastrointestinal symptoms

Based on a systematic review of the literature, including 92 gastric emptying studies (26 breath test, 62 scintigraphy, 1 ultrasound, and 3 wireless motility capsule) there is an association between optimally measured delayed gastric emptying and upper gastrointestinal symptoms[2]. Twenty-five of these studies provided quantitative data for meta-analysis (15 scintigraphy studies enrolling 4056 participants and 10 breath test studies enrolling 2231 participants). Evaluating the studies that used optimal gastric emptying test methodology, there were significant associations between gastric emptying and nausea, vomiting, abdominal pain, and early satiety/fullness in patients with upper gastrointestinal symptoms; gastric emptying and early satiety/fullness in patients with diabetes; and gastric emptying and nausea in patients with gastroparesis.

Gastric motor functions and other features in referred patients with diabetes with upper gastrointestinal symptoms

Among 108 adult patients with diabetes mellitus (60.2% females; median age 49.0 years; 71.3% with type 2 diabetes mellitus; one-third insulin dependent with median hemoglobin A1C 6.7%) presenting with upper gastrointestinal symptoms, the manifestations of diabetic triopathy (peripheral neuropathy, nephropathy, and retinopathy) were uncommon at the time of presentation[3]. Nausea was the most common symptom (80.6%). Gastric emptying was rapid in 37% and slow in 19%. Gastric accommodation was abnormal in 39%. There was normal gastric accommodation and gastric emptying in 28% and 40.3% of the patients with type 2 diabetes mellitus had accelerated gastric emptying at one hour. These observations emphasize the importance of measuring these functions in patients with upper gastrointestinal symptoms in order to individualize treatment, such as with a dopamine D2 antagonist or a 5-hydroxytryptamine receptor (5-HT4) agonist for patients with delayed gastric emptying and a 5-HT1A agonist in patients with impaired gastric accommodation.
Histopathological features and expression in the intrinsic mechanisms involved in gastric motor functions

In different morphological studies based on light microscopy examination of full-thickness gastric biopsies and immunofluorescence, there is evidence of reduction in the pacemaker cell repertoire (interstitial cells of Cajal[4,5] and fibroblast-like cells positive for platelet-derived growth factor alpha[6]), reduced numbers of neurons expressing nNOS[4], and reduced numbers of M2 macrophages, which normally express the mannosese receptors (CD206) and heme oxygenase-1, mediate cell repair, and have anti-inflammatory roles[5].

Other studies show increase in CD68 immunocytes, suggesting immune-mediated damage to these pacing mechanisms[6], and this may be aggravated in the presence of vagal denervation, a common sequel of longstanding type 1 diabetes mellitus. Normally, the efferent vago nerve signals release of norepinephrine from splenic nerves, activating the $\beta$2-adrenergic receptor expressed on T cells, and macrophages and other immune cells, suppressing the release of pro-inflammatory cytokines[7]. In summary, the interplay of vagal neuropathy, intrinsic neuropathy and immune modulation are considered combination factors leading to the gastric motility disorder.

Role of hyperglycemia in diabetic gastroparesis

The role of hyperglycemia in diabetic gastroparesis is unclear. On the one hand, there is epidemiological evidence of association of glycemia with upper gastrointestinal symptoms[8], documentation of poor glycemic control in 36% patients admitted to the hospital for exacerbations of diabetic gastroparesis[9], kidney and pancreas transplants improve gastric emptying and associated gastrointestinal symptoms[10]. Conversely, hemoglobin A1C was not a statistically significant predictor of abnormal (compared to normal) gastric emptying of solids in a study of 129 patients[11], and long-term blood glucose control had no significant effect on gastric emptying in type 2 diabetes mellitus[12].

Role of stomach emptying on glycemic control

The available literature suggests that the stomach emptying does have an impact on glycemic control, and not only in patients with gastroparesis. Some published reports confirm the notion that gastroparesis impacts glycemic control: (1) patients with gastroparesis as documented in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort, gastroparesis was associated with relatively worse glycemic control, as assessed by glycosylated hemoglobin[13]; (2) there is poor glycemic control in 36% patients admitted to the hospital for exacerbations of diabetic gastroparesis[9]; and (3) in insulin-treated patients with gastroparesis, delayed gastric emptying may increase the potential for a mismatch the timing of exogenous, preprandial, insulin and the actual delivery of nutrients such as glucose from the stomach to be absorbed from in the small intestine. In a study involving 11 type 1 patients, less insulin was required to achieve euglycemia during the first 120 min after a meal in the 5 with gastroparesis, and more between 180-240 min[14]. In addition, there is also evidence that the rate of gastric emptying has a major impact on the glycemic response to carbohydrate-containing meals in health and diabetes, particularly the initial postprandial increment[15]. Therefore, it is now appreciated that postprandial glycemic excursions make a major contribution to “overall” glycemic control as assessed by hemoglobin A1C. Delayed gastric emptying in type 1 diabetes has recently been reported to be associated with an overall increase in blood glucose during the day; this may reflect the mismatch between the preprandial insulin and the later absorption of food due to the delayed gastric emptying[16].

OBSERVATIONS RELATED TO GASTROINTESTINAL HORMONES IN OBESITY

Role of gastric emptying in the beneficial effects of GLP-1 analogs

Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for treatment of obesity; however, the mechanisms of action of liraglutide are incompletely understood and include increase in satiety, increase in resting energy expenditure, and direct effects on appetite centers in the brain[17]. In a randomized, double-blind, placebo-controlled trial of subcutaneous liraglutide (3.0 mg) in 40 patients at Mayo Clinic, liraglutide delayed gastric emptying of solids at 5 wk and 16 wk, and there was significantly greater weight loss and lower volume of a nutrient drink to reach the maximum tolerated volume in the liraglutide group than in the placebo group. The effects of liraglutide on weight loss are associated with delay in gastric emptying of solids, and the measurement of gastric emptying (e.g., at 5 wk of treatment) may be a biomarker of responsiveness and may help to select individuals for prolonged treatment with this class of drug[18].

The effect of GLP-1 receptor agonist on weight loss does not appear to be impacted by the presence of metabolic derangements such as type 2 diabetes. However, there is evidence of a significant correlation in the weight loss induced by liraglutide and delay of gastric emptying[18].

Incretin combinations for obesity

Incretin and pancreatic hormones [e.g., amylin, glucagon, glucose-stimulated insulinotropic peptide (GIP), GLP-1 and peptide tyrosine tyrosine (PYY)] generally inhibit upper gastrointestinal motor function[19] or secretion (e.g., oxyntomodulin). Moreover, many of these hormones also exert central effects that reduce appetite[20], and some
(e.g., GLP-1 analogs or GLP-1 receptor agonists) are efficacious in the treatment of obesity. Several combined incretin hormones have been tested in the context of obesity. Co-administration of GLP-1 with glucagon in humans increased energy expenditure and reduced food intake. A unimolecular dual incretin consisting of PEGylated GLP-1 and GIP co-agonist maximized metabolic benefits in rodents, monkeys, and humans. The combination of GLP-1 and PYY3–36 also exerts synergistic effects with a reduction of 30.4% of food intake compared to placebo and more than the sum of each hormone independently, suggesting a synergistic effect. Acute, continuous, subcutaneous infusion for 10.5 h/d of GLP-1, PYY, and oxyntomodulin (summarized as GOP) was administered at doses that replicate postprandial levels observed after Roux-en-Y gastric bypass in a placebo-controlled, crossover study. GOP reduced food intake with a mean reduction of 32% without significantly altering resting energy expenditure.

**Combined bariatric endoscopy with pharmacotherapy**

One study compared the effects of an intragastric balloon in 64 patients compared to a combination of balloon plus liraglutide, up to 1.8 mg/d, in 44 patients matched for body mass index (BMI) at baseline. The mean weight loss after balloon removal was 8.3 kg greater in the balloon plus liraglutide group than in the balloon alone group, and the advantage persisted 6 mo post-balloon removal in the group receiving liraglutide.

**BARIATRIC ENDOSCOPIC PROCEDURES**

The development of endoscopic interventions for treatment of obesity and diabetes mellitus has focused on two areas (Table 1), the placement of intraluminal devices and intraluminal suturing.

**Intraluminal devices**

The first intragastric balloon, the Garren-Edwards bubble, was approved by the United States Food and Drug Administration in 1985. The United States Food and Drug Administration has now approved 3 separate intragastric balloon systems in the past 3 years: The Orbera balloon, the ReShape balloon, and the Obalon balloon. Delayed gastric emptying has been identified as a mechanism for weight loss in individuals who have undergone insertion of a fluid-filled intragastric balloon, which raises the question of their utility in individuals with diabetic gut autonomic neuropathy. After the intraluminal balloons are removed, individuals required a maintenance program (which has not yet been standardized) to prevent weight regain. Our previous concern that specialized training is needed for the use of these devices appears to be supported by three warnings (in February 2017, August 2017, and June 2018) from the United States Food and Drug Administration with regards to issues related to intragastric balloons including multiple deaths related to intragastric balloons. Two major reviews in the past two years examined the 30+ years experience with intragastric balloons. Brethauer et al. concluded that more study was required in patients with type 2 diabetes mellitus. Popov et al. concluded that intragastric balloons were more effective that diet alone for an initial improvement of metabolic risk factors, but that their conclusions are limited by the small number of participants and the lack of long-term follow-up data.

Some countries have the availability of a duodeno-jejunal bypass sleeve, termed the EndoBarrier. This impermeable fluoropolymer sleeve with a nitinol anchor is deployed from the duodenal bulb and into the jejunum under fluoroscopic and endoscopic guidance. A clinical trial of this device in the United States in individuals with diabetes mellitus was halted early due to the development of liver infections. Three studies involving the EndoBarrier in individuals with type 2 diabetes mellitus have been published in the past one year. Betzel et al. were able to implant the device in 185 out of 198 participants. Sixty-nine percent of the participants were able to complete a one year program prior to removal of the device. Hemoglobin A1C levels declined by a mean of 9%, but no long term data was available. Forner et al. reported their findings in 114 individuals who maintained an EndoBarrier for a mean of 51.1 wk after its placement; the authors reported that mean Hemoglobin A1C was not significantly improved but that 6 subjects developed device obstructions, 5 individuals had gastrointestinal hemorrhage, 2 individuals developed liver abscesses, and 1 individual developed acute pancreatitis. Patel et al. reported a multicenter trial involved EndoBarrier Placement in 45 individuals with type 2 diabetes. Thirty-one individuals (69%) completed the 12 mo study. The mean hemoglobin A1C reduction at 12 mo was 0.8% below baseline. After explant, these subjects were only followed for an additional 6 mo.

The AspireAssist (Aspire Bariatrics, King of Prussia, Pennsylvania, United States) was approved by the United States Food and Drug Administration in 2016. A specialized aspiration tube (with both an intragastric portion with holes to permit aspiration as well as a skin port) is placed percutaneously at upper endoscopy into an individual’s stomach. Stomach contents are then

| Table 1 Bariatric endoscopic procedure |
|---------------------------------------|
| Intraluminal devices                  |
| Intragastric balloon                  |
| Orbera†                               |
| ReShape†                              |
| Obalon†                               |
| Duodeno-jejunal bypass sleeve (EndoBarrier) |
| Aspiration therapy (AspireAssist)     |
| Intraluminal suturing                 |
| Endoscopic sleeve gastroplasty       |
| Transoral gastroplasty                |

†In order of date approved by United States Food and Drug Administration.
The top cartoon depicts the adjustable gastric band which limits the types of food consumed postoperatively by patients. The middle cartoon depicts the vertical sleeve gastrectomy which limits the volume of food consumed postoperatively by patients. The lower cartoon depicts the Roux-en-Y gastric bypass which limits volume of food consumed, may alter absorption of macronutrients, and alters release of intestinal incretins (Reproduced with the permission of Nature Publishing Group from Bal et al. Nature Rev Endocrinol 2012; 8: 544-556).

As described above, long-term weight loss and metabolic results are not available for these endoscopic devices. Therefore their role in the treatment of obese individuals with diabetes mellitus remains to be defined.

**Intraluminal suturing**

Formation of an endoscopic sleeve gastroplasty or a transoral gastroplasty has been described by using intraluminal suturing devices during upper endoscopy. The Mayo Clinic, Rochester, Minnesota United States reported their method in 2013 for an endoscopic sleeve gastrectomy (Figure 1). By 2014, there were 579,000 yearly bariatric surgical procedures of which 45.9% were the vertical sleeve gastrectomy, 39.6% were the Roux-en-Y gastric bypass, and 7.4% were the adjustable gastric band. The adjustable gastric band systems now use a soft, silicone ring which is placed around the upper part of the stomach approximately 4 cm below the gastroesophageal junction and is connected to an access port by tubing to adjust the band volume. Restriction of the proximal stomach is altered by addition or removal of sterile saline through the access port and there is no cutting or stapling of the stomach or bypass of small intestine. The vertical sleeve gastrectomy or gastric sleeve resection can be completed with a single step restrictive operation. By resection of 60% to 80% of the stomach along the greater curvature, multiple staplers can produce a tubular gastric pouch. Weight loss after vertical sleeve gastrectomy appears to involve several potential mechanisms in addition to restriction in the size of meal portions. In the Roux-en-Y gastric bypass, there is complete division of native stomach with production of a gastric pouch of less than 30 mL. The surgeon divides the jejunum 30 to 70 cm distal to the junction of the duodenum with the jejunum. The location of the jejuno-enteric anastomosis determines the lengths of the Roux limb (e.g., the gastric pouch to the jejuno-enteric anastomosis) and the common channel (e.g., the jejuno-enteric anastomosis to the ileocecal valve). A common channel that is shorter than 120 cm can induce a severe malabsorptive disorder. The mechanisms of weight loss after gastric bypass are complex and can include upper gut bacterial overgrowth, a common intestinal disorder in individuals with diabetes mellitus, as well as glucose malabsorption. Studies of glucose malabsorption after gastric bypass are of interest because jejunal administration of glucose appears to suppress plasma levels of the orexigenic hormone, acyl ghrelin. Further studies of the mechanisms of weight loss after bariatric surgery are clearly important since a proportion of individuals have poor long-term weight loss.
Table 2 Long term weight loss after bariatric surgery

| Ref. | Study | Type of surgery | Follow up | Result (%) |
|------|-------|----------------|----------|------------|
| [52] | MA    | AGB            | ≥ 10 yr  | EWL: 47.4  |
| [52] | MA    | VSG            | ≥ 5 yr   | EWL: 53.2  |
| [52] | MA    | RYGB           | ≥ 10 yr  | EWL: 63.5  |
| [44] | MCS   | AGB            | 15 yr    | MWL: 13.0  |
| [44] | MCS   | RYGB           | 15 yr    | MWL: 27.0  |
| [53] | SCS   | VSG            | 8 yr     | EWL: 67.0  |
| [54] | SCS   | VSG            | 8 yr     | EWL: 51.1  |
| [55] | MCS   | VSG            | 10 yr    | EWL: 70.5  |
| [56] | SR    | AGB            | 3-5 yr   | EWL: 45.0  |
| [56] | SR    | VSG            | 3-5 yr   | EWL: 64.5  |
| [56] | SR    | RYGB           | 3-5 yr   | EWL: 65.7  |

*MA: Meta-analysis; MCS: Multi-center study; SCS: Single-center study; SR: Systematic review; AGB: Adjustable gastric band; VSG: Vertical sleeve gastrectomy; RYGB: Roux-en-Y gastric bypass; EWL: Mean percentage excess weight loss; MWL: Mean weight loss.

Long term mortality after bariatric surgery

The potential importance of bariatric surgery in individuals with diabetes mellitus was well publicized following a 2007 report that after a mean follow up of 7.1 years, individuals who underwent gastric bypass surgery had a 40% decrease in their adjusted long-term mortality (but by 92% for diabetes) compared to the control group.[43] This landmark study has been supported by a report of decreased mortality compared to usual care at 16 years in the Swedish Obese Subjects trial.[44] In a national study from Israel, bariatric surgery at a mean follow up of 4.5 years was shown to lower all-cause mortality compared to usual care obesity management[45]. Finally, in a recent examination of the American National Health and Nutrition Examination Survey, it was reported that bariatric surgery can result in a relevant reduction of mortality in the United States obese population.[46]

Long term weight loss after bariatric surgery

Evaluation of the results reported for the different major bariatric surgical procedures may vary dependent upon whether single center data or multicenter data is examined. The largest discrepancy appears in reports concerning the adjustable gastric band, which may in part explain its decreased worldwide utilization. Several major reports in the past one year have supported major weaknesses of the adjustable band. In a single center report from Switzerland, after over 10 years of follow up, 71% of patients had lost their gastric band and only 15% of patients had good to excellent results.[47] In a French national study of 52868 patients up to 7 years after adjustable gastric banding, the band removal rate was about 6% per year.[48] In a study from the state of New York, among 16444 patients who underwent adjustable gastric banding, with at least four years of follow up the rate of revisions/conversions was 26.0%. [49] An early meta-analysis reported that bariatric surgery does result in a weight loss of 20 to 30 kg, which is maintained for up to 10 years.[50] A follow up meta-analyses in 2013 by Goy and associates reported in a shorter follow up that individuals allocated to bariatric surgery lost a mean of 26 kg more body weight,[51] Representative reports of long-term weight loss after bariatric surgery are summarized in Table 2. The most effective bariatric surgical procedure for weight loss at up to 15 years of post-operative follow up is the Roux-en-Y gastric bypass surgery.[44,52] The least effective major bariatric surgical procedure in long term studies of weight loss is the adjustable gastric band.[44,52,56].

Long term control of diabetes mellitus after bariatric surgery

A joint statement by international diabetes organizations supports consideration of bariatric surgery in individuals with diabetes mellitus and: BMI ≥ 40 kg/m², BMI 35-39.9 kg/m² and inadequate control of hyperglycemia with optimal medical therapy, or BMI 30-34.9 kg/m² and inadequate control of hyperglycemia with oral or injectable medications.[53] In the United States, individuals with diabetes mellitus considering bariatric surgery are evaluated if they fulfill National Institutes of Health criteria, which is a BMI of ≥ 35 kg/m², while in other countries individuals with diabetes and a BMI as low as 25 kg/m² may be considered for Roux-en-Y gastric bypass. Specific bariatric surgical procedures such as the vertical sleeve gastrectomy may not be effective for treatment of individuals with type 1 diabetes mellitus.[54] A meta-analysis comparing non-surgical treatment for obesity with bariatric surgery concluded that individuals allocated to bariatric surgery had a higher remission rate of type 2 diabetes.[55] A second meta-analysis with 5 years of follow-up confirmed a significant decline in the relative risk of diabetes after bariatric surgery.[56] Representative reports of long-term control of diabetes mellitus after bariatric surgery are summarized in Table 3. The most effective bariatric surgical procedure for remission of diabetes mellitus at up to 6 years of post-operative follow up is the Roux-en-Y gastric bypass surgery.[57,58] The least effective major bariatric surgical procedure in long term studies of remission of diabetes mellitus is the adjustable gastric band.[56,58] The importance of remission of diabetes is supported by a report of decreased incidence of microvascular and macrovascular complications in post-operative bariatric patients compared to controls.[59] These published results do support the importance of ongoing development of more effective bariatric surgical procedures for the treatment of individuals with obesity and type 2 diabetes mellitus.

BARIATRIC PROCEDURES UNDER DEVELOPMENT

Gastrointestinal surgeons who specialize in bariatics have seen an improvement in weight related comorbidities for decades. Encouraged by mounting evidence of resolution...
or substantial improvement in diseases such as diabetes mellitus, hyperlipidemia, and hypertension, leaders in the field created a paradigm shift by renaming the American Society of Bariatric Surgery as the American Society of Metabolic and Bariatric Surgery in 2007 (ASMBS.org; accessed on July 15, 2018). Gastrointestinal surgeons continue to manipulate the gastrointestinal tract in an effort to maximize the physiologic benefit to the individual patient. Restrictive procedures (i.e., vertical sleeve gastrectomy, adjustable gastric banding, and the largely abandoned vertical banded gastroplasty) provide a benefit usually in proportion to the absolute weight loss achieved. Newer endoscopic and surgical procedures including the intragastric balloon, vBloc (described below), and aspirational therapy have more modest results.

Procedures that combine restriction with malabsorption by bypassing a portion of the foregut and midgut do provide measurable changes in comorbid conditions out of proportion to absolute weight loss. The traditional “gold standard” of surgical weight loss procedures, the Roux-en-Y gastric bypass, can provide rapid glucose control for patients. This procedure may take advantage of the “foregut hypothesis” that bypassing the foregut reduces or suppresses the secretion of anti-incretin hormones, which in turn leads to improvement of blood glucose control[64]. Proponents of the “hindgut hypothesis” feel this improvement is more likely secondary to rapid delivery of nutrients to the distal small intestine, which facilitates the release of hormones such as GLP-1[64,65]. Procedures which take advantage of this scenario include the bilipancreatic diversion/duodenal switch. Based upon these previous observations and notions, more recent modifications to this malabsorption procedure have shown favorable results in treatment of metabolic diseases, with up to 4 years of follow up[66,67]. Further refinements in these procedures will likely yield more promising results which may be able to be individualized for specific patient needs.

Another area of ongoing, active clinical research has been vagal nerve stimulation, based on the important role the vagus nerve plays in regulation pathways involving short-term regulation of dietary intake. The therapy termed vBloc for Vagal BLOCking therapy (ReShape Lifesciences, San Clemente, California United States) uses intermittent intra-abdominal high-frequency electrical currents for vagal blocking. At laparoscopy, electrodes are placed on the two vagal trunks near the gastroesophageal junction. There is no anatomical modification and an external controller is used to program the device. Vagal nerve stimulation with vBloc in a 2 year study has shown promise for weight loss (mean of 21% of excess weight loss), but with only an marginal impact on diabetes (only a 0.3% decline in hemoglobin A1C[68]). Further evaluation is therefore required to determine which patients with obesity and diabetes mellitus may benefit from this bariatric procedure.

**CONCLUSION**

The worldwide prevalence of obesity continues to rise. This rise increases the incidence of type 2 diabetes mellitus with subsequent requirements for additional health care in countries across the world. This supports the need for an increased interaction between ongoing clinical research in the allied fields of gastrointestinal medicine/surgery and diabetes mellitus. Among the clinically-relevant advances in diabetes, obesity, and metabolic syndrome emanating from gastroenterological research, delayed gastric emptying and impaired gastric accommodation result in upper gastrointestinal symptoms, through intrinsic nerve and pacemaker dysfunction. Glycemic control has a limited effect on metabolic syndrome, but treatment of diabetes with pancreatic hormones and incretins inhibits gastric emptying, reduces hyperglycemia, and facilitates weight loss. The GLP-1 analog, liraglutide, is one of the two most efficacious treatments of obesity. New bariatric endoscopic procedures have been developed for weight loss in individuals with obesity, but long term follow-up with regards to maintenance of weight loss and control of hyperglycemia in individuals with diabetes is required prior to mass introduction of these endoscopic interventions. Bariatric surgical procedures are efficacious
in diabetes and obesity, but a proportion of individuals have poor long-term weight loss after bariatric surgery. On the horizon, combination therapies directed at gastrointestinal function and newer bariatric surgical procedures appear promising for individuals with obesity and type 2 diabetes mellitus.

REFERENCES

1. GBD 2015 Obesity Collaborators., Afshin A, Forouzanfar MH, Reitsma MB, Sur P, E斯特 K, Lee A, Marczak L, Mokdad AH, Moradi-Lakeh M, Naghavi M, Salama JS, Vos T, Abate KH, Abbafati C, Ahmed MB, Al-Aly Z, Akerwi A, Al-Raddadi R, Amare AT, Amberbir A, Amegah AK, Aminni E, Amro EM, Anjana RM, Amiló J, Asayesh H, Banerjee A, Barac A, Baye E, Bennett DA, Beyene AS, Biadgilign S, Biryukov S, Brandler J, Vijayvargiya P, Park SY, Szarka LA, Nakamura T, Kasai F, Onuma T, Baba T, Takebe K, 2015; Farrugia G, Lurken MS, Bernard CE, Faussone-Pellegrini SM, Smyrk TC, Parkman HP, Abell TL, Snape WJ, Hasler WL, Ūnalp-Arida A, Nguyen L, Koch KL, Calles J, Lee L, Tonascia J, Hamilton FA, Pasricha PJ, NIDDK Gastroparesis Clinical Research Consortium (GpCRC). Association of low numbers of CD206-positive cells with loss of ICC in the gastric body of patients with diabetic gastrroparesis. Neurogastroenterol Motil 2014; 26: 1275-1284 [PMID: 25041465 DOI: 10.1111/nmo.12389]

2. Vijayvargiya P, Jamei-Oskooei S, Camilleri M, Chedid V, Erwin PJ, Murad MH. Association between delayed gastric emptying and upper gastrointestinal symptoms: a systematic review and meta-analysis. Gut 2018 [PMID: 29860241 DOI: 10.1136/gutjnl-2018-316405]

3. Chedid V, Brandler J, Vijayvargiya P, Park SY, Szarka LA, Camilleri M. Characterization of Upper Gastrointestinal Symptoms, Gastric Motor Functions, and Associations in Patients with Diabetes at a Referral Center. Am J Gastroenterol 2018 [PMID: 30166634 DOI: 10.1038/s41398-018-0243-1]

4. Grover M, Farrugia G, Lurken MS, Bernard CE, Faussone-Pellegrini SM, Smyrk TC, Parkman HP, Abell TL, Snape WJ, Hasler WL, Ūnalp-Arida A, Nguyen L, Koch KL, Calles J, Lee L, Tonascia J, Hamilton FA, Pasricha PJ; NIDDK Gastraparesis Clinical Research Consortium. Cellular changes in diabetic and idiopathic gastrroparesis. Gastroenterology 2011; 140: 1575-85.e8 [PMID: 2130066 DOI: 10.1053/j.gastro.2011.01.046]

5. Bernard CE, Gibbons SJ, Mann JS, Froschauer L, Parkman HP, Harbison S, Abell TL, Snape WJ, Hasler WL, McCullum RW, Srosciecki I, Nguyen L, Koch KL, Tonacca J, Hamilton FA, Kendrick ML, Shn KR, Pasricha PJ, Farrugia G; NIDDK Gastraparesis Clinical Research Consortium (GPgCRC). Association of low numbers of CD206-positive cells with loss of ICC in the gastric body of patients with diabetic gastroparesis. Neurogastroenterol Motil 2014; 26: 1275-1284 [PMID: 25041465 DOI: 10.1111/nmo.12389]

6. Herring BP, Hoggatt AM, Gupta A, Griffith S, Nakeeb A, Choi JN, Idrees MT, Nowak T, Morris DL, Wo JM. Idiopathic gastroparesis is associated with specific transcriptional changes in the gastric muscularis externa. Neurogastroenterol Motil 2018; 30: e13230 [PMID: 29052290 DOI: 10.1111/nmo.13230]

7. Han B, Li X, Hao J. The cholinergic anti-inflammatory pathway: An innovative treatment strategy for neurological diseases. Neurosci Biobehav Rev 2017; 77: 358-368 [PMID: 28392244 DOI: 10.1016/j.neubiorev.2017.04.002]

8. Bytzger P, Talley NJ, Hammer J, Young LJ, Jones MP, Horowitz M. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am J Gastroenterol 2002; 97: 604-611 [PMID: 11922554 DOI: 10.1111/j.1572-0241.2002.05537.x]

9. Uppalapati SS, Ramzan Z, Fisher RS, Parkman HP. Factors contributing to hospitalization for gastroparesis exacerbations. Dig Dis Sci 2009; 54: 2404-2409 [PMID: 19760157 DOI: 10.1007/s10620-009-0975-1]

10. Gaber AO, Oxley D, Karis J, Cardoso S, Hathaway D, Shokouh-Amiri MH, Jensen SL, Abell TL. Changes in gastric emptying in recipients of successful combined pancreas-kidney transplants. Dig Dis Sci 1991; 36: 437-443 [PMID: 1804583 DOI: 10.1001/1804583]

11. Bharucha AE, Camilleri M, Forstrom LA; Zinsmeister AR. Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. Clin Endocrinol (Oxf) 2009; 70: 415-420 [PMID: 18727706 DOI: 10.1111/j.1365-2265.2008.03351.x]

12. Holzapfel A, Festa A, Stacher-Jannotta G, Bergmann H, Shnawa N, Bumann W, Scherntenher G, Stacher G. Gastric emptying in Type II (non-insulin-dependent) diabetes mellitus before and after therapy readjustment: no influence of actual blood glucose concentration. Diabetologia 1999; 42: 1410-1412 [PMID: 10651258 DOI: 10.1007/s001250051311]

13. Bharucha AE, Batey-Schaefer A, Cleary PA, Murray JA, Cowie C, Lorenzi G, Driscoll M; Harth J, Larkin M, Christofi M, Bayless M, Wimmergren N, Herman W, Whitehouse F, Jones K, Kruger D, Martin C, Ziegler G, Zinsmeister AR, Nathan DM; Diabetes Control and Complications Trial-Epidemiology of Diabetes Interventions and Complications Research Group. Delayed Gastric Emptying Is Associated With Early and Long-term Hyperglycemia in Type 1 Diabetes Mellitus. Gastroenterology 2015; 149: 330-339 [PMID: 25980755 DOI: 10.1053/j.gastro.2015.05.007]

14. Ishii M, Nakamura T, Kasai F, Onuma T, Baba T, Takeke K. Altered postprandial insulin requirement in IDDM patients with diabetes. Gastroenterology 1994; 107: 901-903 [PMID: 7966640 DOI: 10.1016/j.gastro.2017.01.046]

15. Phillips LK, Deane AM, Jones KL, Rayner CK, Horowitz M. Gastric emptying and glycaemia in health and diabetes mellitus. Nat Rev Endocrinol 2015; 11: 112-128 [PMID: 25421372 DOI: 10.1038/nrendo.2014.202]

16. Parthasarathy G, Kudva YC, Low PA, Camilleri M, Basu A, Bharucha AE. Relationship Between Gastric Emptying and Diurnal Glycaemic Control in Type 1 Diabetes Mellitus: A Randomized Trial. J Clin Endocrinol Metab 2017; 102: 398-406 [PMID: 27880079 DOI: 10.1210/jc.2016-2809]

17. Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jas T, Zdravkovic M, Chapman IM. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract 2012; 97: 258-266 [PMID: 22446907 DOI: 10.1016/j.diabres.2012.02.016]

18. Halawi H, Khemani D, Eckert D, O’Neill J, Kadouh H, Grothe K, Clark MM, Burton DD, Vella A, Acosta A, Zinsmeister AR, Camilleri M. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol 2017; 2: 890-899 [PMID: 28958851 DOI: 10.1016/S2468-1253(17)30285-6]

19. Camilleri M. Integrated upper gastrointestinal response to food intake. Gastroenterology 2006; 131: 640-658 [PMID: 16890616 DOI: 10.1053/j.gastro.2006.03.023]

20. Zanchi D, Depooter A, Egloff L, Haller S, Mählmann L, Lang
